Colinz Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹38.7
- Today's High:
- ₹42.7
- Open Price:
- ₹42.7
- 52W Low:
- ₹31.6
- 52W High:
- ₹61.15
- Prev. Close:
- ₹40.73
- Volume:
- 2798
Company Statistics
- Market Cap.:
- ₹24.64 million
- Book Value:
- 14.959
- Revenue TTM:
- ₹69.94 million
- Operating Margin TTM:
- 1.43%
- Gross Profit TTM:
- ₹48.25 million
- Profit Margin:
- 1.89%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Colinz Laboratories Limited had its IPO on under the ticker symbol 531210.
The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Colinz Laboratories Limited has a staff strength of 56 employees.
Stock update
Shares of Colinz Laboratories Limited opened at ₹42.7 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹38.7 - ₹42.7, and closed at ₹41.38.
This is a +1.6% increase from the previous day's closing price.
A total volume of 2,798 shares were traded at the close of the day’s session.
In the last one week, shares of Colinz Laboratories Limited have slipped by -0.17%.
Colinz Laboratories Limited's Key Ratios
Colinz Laboratories Limited has a market cap of ₹24.64 million, indicating a price to book ratio of 0.5108 and a price to sales ratio of 0.547.
In the last 12-months Colinz Laboratories Limited’s revenue was ₹69.94 million with a gross profit of ₹48.25 million and an EBITDA of ₹2.90 million. The EBITDA ratio measures Colinz Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Colinz Laboratories Limited’s operating margin was 1.43% while its return on assets stood at 0% with a return of equity of 0%.
In Q3, Colinz Laboratories Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 30.1%.
Colinz Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 12.609
- PEG
Its diluted EPS in the last 12-months stands at ₹0.733 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Colinz Laboratories Limited’s profitability.
Colinz Laboratories Limited stock is trading at a EV to sales ratio of 0.0705 and a EV to EBITDA ratio of 1.1469. Its price to sales ratio in the trailing 12-months stood at 0.547.
Colinz Laboratories Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹102.31 million
- Total Liabilities
- ₹18.86 million
- Operating Cash Flow
- ₹87000.00
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Colinz Laboratories Limited ended 2024 with ₹102.31 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹102.31 million while shareholder equity stood at ₹81.39 million.
Colinz Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹18.86 million in other current liabilities, 25191000.00 in common stock, ₹56.20 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹19.65 million and cash and short-term investments were ₹57.29 million. The company’s total short-term debt was ₹2,734,000 while long-term debt stood at ₹0.
Colinz Laboratories Limited’s total current assets stands at ₹78.35 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹11.34 million compared to accounts payable of ₹0 and inventory worth ₹9.39 million.
In 2024, Colinz Laboratories Limited's operating cash flow was ₹87000.00 while its capital expenditure stood at ₹0.
Comparatively, Colinz Laboratories Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹41.38
- 52-Week High
- ₹61.15
- 52-Week Low
- ₹31.6
- Analyst Target Price
- ₹
Colinz Laboratories Limited stock is currently trading at ₹41.38 per share. It touched a 52-week high of ₹61.15 and a 52-week low of ₹61.15. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹37.74 and 200-day moving average was ₹40.27 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3642% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Colinz Laboratories Limited
Similar Industry Stocks (Drug Manufacturers - Major)
Most Active
Top Gainers
Top Losers
About
Colinz Laboratories Limited manufactures and markets pharmaceutical formulations in India It provides pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, etc.; and specialized products for gynecology, cardiology, gastroenterology, etc. The company’s allopathy products include oncology products and antiritrovirals; and products for other therapeutic areas, such as antibiotics, anti-pyretics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anti-diarrhoeals, anti-inflammatory, anti-piles, anthelmintics, anti-emetics, anti-spasmodics, infestations, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormone, sunscreens and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. It also provides ayurvedic products, including anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, apetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, ear drops, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. In addition, the company offers nutraceuticals that include spirulina tabs/caps; spirulina with vitamins and minerals; omega 3 fatty acids caps in softgel; codliver oil with vitamin caps in soft gel; collagen, glucosamine, and chondroitin tabs; amino acids tabs/caps; L-arginine with proantocyanidin granules; and hair growth formulas, etc. The company was founded in 1986 and is based in Mumbai, India.